RAMM Pharma Corp. (RAMM.CN) Research

RAMM Pharma Corp., established in Toronto, Canada, in 1987, focuses on the comprehensive lifecycle of various health and wellness products. The company is engaged in the creation, manufacturing, and distribution of cannabinoid-based pharmaceutical drugs, conventional medications, beauty products, nutritional supplements, and also resells medical equipment to both Canadian and international markets. Its portfolio features key products such as Epifractán, a cannabinoid-infused pharmaceutical; XALEX 10, a prescription formulation designed to treat stubborn cases of epilepsy; and NettaLife, a cannabis-derived product specifically for pets. The firm adopted its current name, RAMM Pharma Corp., in October 2019, having previously operated as MTC Growth Fund-I Inc.

Market snapshot

Symbol
RAMM.CN
Price
$0.02
Day change
0.00%
Market cap
$1.8M
P/E ratio
-0.21x
52-week range
0.01-0.25
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Captor Capital Corp. (CPTR.CN)
  • Copland Road Capital Corporation (CRCC.CN)
  • Ovation Science Inc. (OVAT.CN)
  • Planet Based Foods Global Inc. (PBF.CN)
  • Premier Health of America Inc. (PHA.V)
  • Pharmadrug Inc. (PHRX.CN)
  • Psyence Group Inc. (PSYG.CN)
  • TILT Holdings Inc. (TILT.NE)

Open RAMM Pharma Corp. (RAMM.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.